PE20010284A1 - El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral - Google Patents

El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral

Info

Publication number
PE20010284A1
PE20010284A1 PE2000000373A PE0003732000A PE20010284A1 PE 20010284 A1 PE20010284 A1 PE 20010284A1 PE 2000000373 A PE2000000373 A PE 2000000373A PE 0003732000 A PE0003732000 A PE 0003732000A PE 20010284 A1 PE20010284 A1 PE 20010284A1
Authority
PE
Peru
Prior art keywords
ribavirin
day
antioxidant
vitamin
alpha
Prior art date
Application number
PE2000000373A
Other languages
English (en)
Inventor
Paul W Glue
Clifford A Brass
Edward Piken
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010284A1 publication Critical patent/PE20010284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

SE REFIERE AL USO DE a)UN ANTIOXIDANTE TAL COMO VITAMINA A, VITAMINA E, VITAMINA C, COENZIMA Q10, HIDROXIANISOL BUTILADO (BHA), HIDROXITOLUENO BUTILADO (BHT), N-ACETILCISTEINA, SELENIO, PANAVIR (4,4`-ISOPROPILDITIOBIS-2,6-DI-t-BUTILFENOL), SILYBUM MARIANUM, LICOPENO; a, d-ALFA TOCOFERIL ESTER, ESTER DE ALFA-TOCOFERIL POLIETILEN GLICOL SUCCINATO, PARA MEJORAR LA HEMOLISIS RELACIONADA CON LA RIBAVIRINA; b)UNA CANTIDAD TERAPEUTICAMENTE DE RIBAVIRINA SUFICIENTE COMO PARA BAJAR DEL ARN VIRAL DETECTABLE. SE REFIERE ADEMAS AL USO DE UNA COMBINACION DE 600 mg/DIA A 1600 mg/DIA DE RIBAVIRINA CON INTERFERON ALFA 2a O 2b TRATADO CON PEG O UN INTERFERON CONCENSUAL O UN PRODUCTO DE INTERFERON ALFA PURIFICADO; POR UN PRIMER PERIODO DE 24 SEMANAS; LUEGO EL USO DE 600 mg/DIA A 1600 mg/DIA DE RIBAVIRINA CON EL ANTIOXIDANTE POR UN SEGUNDO PERIODO DE 24 SEMANAS; PUDIENDO SER UTIL PARA EL TRATAMIENTO DE INFECCIONES POR HEPATITIS C CRONICA
PE2000000373A 1999-04-19 2000-04-19 El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral PE20010284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29468799A 1999-04-19 1999-04-19

Publications (1)

Publication Number Publication Date
PE20010284A1 true PE20010284A1 (es) 2001-03-05

Family

ID=23134504

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000373A PE20010284A1 (es) 1999-04-19 2000-04-19 El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral

Country Status (14)

Country Link
EP (1) EP1046399A1 (es)
JP (1) JP2002542202A (es)
CN (1) CN1355708A (es)
AR (1) AR023541A1 (es)
AU (1) AU4463300A (es)
BR (1) BR0009840A (es)
CA (1) CA2306039A1 (es)
CO (1) CO5241354A1 (es)
HU (1) HUP0200942A3 (es)
MX (1) MXPA00003974A (es)
NO (1) NO20015059L (es)
PE (1) PE20010284A1 (es)
WO (1) WO2000062799A1 (es)
ZA (1) ZA200108571B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
TWI274585B (en) * 2002-06-03 2007-03-01 Nat Health Research Institutes Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20060088502A1 (en) * 2003-02-21 2006-04-27 Michio Sata Drug for reducing side effects in ribavirin interferon combination therapy
ZA200601181B (en) * 2003-08-13 2007-04-25 Smith Howard J & Ass Pty Ltd Method of treating viral infections
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
CO5241354A1 (es) 2003-01-31
AU4463300A (en) 2000-11-02
CN1355708A (zh) 2002-06-26
JP2002542202A (ja) 2002-12-10
EP1046399A1 (en) 2000-10-25
HUP0200942A2 (hu) 2002-07-29
MXPA00003974A (es) 2002-03-08
CA2306039A1 (en) 2000-10-19
WO2000062799A1 (en) 2000-10-26
HUP0200942A3 (en) 2003-03-28
BR0009840A (pt) 2002-01-08
ZA200108571B (en) 2003-01-20
NO20015059D0 (no) 2001-10-18
AR023541A1 (es) 2002-09-04
NO20015059L (no) 2001-12-19

Similar Documents

Publication Publication Date Title
PE20010284A1 (es) El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral
SV2002000097A (es) Inhibidores de metaloproteasas ref.pcs10322/82940 /bb
ATE269321T1 (de) Arzneimittel gegen virale erkrankungen
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
MY125921A (en) Compositions containing organic compounds
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
AR019855A1 (es) Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica
UY29172A1 (es) Composición de trombina estable
BR0214277A (pt) Solvatos de paclitaxel
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
BRPI0412798A (pt) uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
GB0217294D0 (en) Medicaments
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
WO2004032866A3 (en) Therapeutic formulations
PL369754A1 (en) Immunocytokine-containing lyophilized preparation
AR047880A1 (es) COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
NI200700176A (es) Compuestos peptídicos
EA200400591A1 (ru) СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИН α1
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
DK1605957T3 (da) Anvendelse af lupin-konglutin til behandling af type II-diabetes
ATE401098T1 (de) Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
ATE439126T1 (de) Antitumorale terpen-verbindungen
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono

Legal Events

Date Code Title Description
FC Refusal